A Phase 3 Trial To Evaluate The Effectiveness of Fragmin compared to placebo on the healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease (PAOD).

Trial Profile

A Phase 3 Trial To Evaluate The Effectiveness of Fragmin compared to placebo on the healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease (PAOD).

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Diabetic foot ulcer; Embolism and thrombosis; Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2013 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 17 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 19 Nov 2009 Pfizer Company added as trial sponsor as reported by UKCRN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top